Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s stock price fell 6% during mid-day trading on Thursday . The stock traded as low as $29.20 and last traded at $29.74. 329,691 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 657,366 shares. The stock had previously closed at $31.65.
Metsera Stock Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- NYSE Stocks Give Investors a Variety of Quality Options
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- What is the S&P 500 and How It is Distinct from Other Indexes
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
